یادداشتهای مربوط به کتابنامه ، واژه نامه و نمایه های داخل اثر
متن يادداشت
Includes bibliographical references and index.
یادداشتهای مربوط به مندرجات
متن يادداشت
Overview of companion diagnostics (CDx) For precision medicine -- Companion diagnostic (CDx) tests in clinical laboratory improvement amendments (CLIA)-certified laboratories -- Quantitative polymerase chain reaction for companion diagnostics and precision medicine application -- Protein biomarker signatures in precision diagnostics of cancer -- Next-generation sequencing (NGS) for companion diagnostics (CDx) and precision medicine.
بدون عنوان
0
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
There is a new trend in anti-cancer therapeutics development: a targeted therapy and precision medicine that targets a subgroup of patients with specific biomarkers. An in vitro diagnostic (IVD) assay is required to identify a subgroup of cancer patients who would benefit from the targeted therapy, or not likely benefit, or have a high risk of side effects from the specific drug treatment. This IVD or medical device is called a companion diagnostic (CDx) assay. It is key to have a robust CDx assay or device for the success of targeted therapy and precision medicine. This book covers the technical, historical, clinical, and regulatory aspects of CDx in precision medicine. Clearly, more and more newly developed oncology drugs will require accompanying CDx assays, and this book, with chapters contributed by renowned oncologists, provides a comprehensive foundation for the knowledge and application of CDx for precision medicine.
یادداشتهای مربوط به سفارشات
منبع سفارش / آدرس اشتراک
Ingram Content Group
شماره انبار
9781000007213
ویراست دیگر از اثر در قالب دیگر رسانه
عنوان
Companion diagnostics (CDx) in precision medicine.